CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer

被引：0

作者：

Matsubara, N. ^{[1
]}

Agarwal, N. ^{[2
]}

Smith, M. R. ^{[3
]}

Mckay, R. R. ^{[4
]}

Todenhofer, T. ^{[5
]}

Piulats Rodriguez, J. M. ^{[6
]}

Chung, K. L. ^{[7
]}

Heirich, D. ^{[8
]}

Sherwood, S. ^{[9
]}

Schaverien, C. ^{[10
]}

Fasnacht, N. ^{[11
]}

Lithio, A. ^{[12
]}

Nacerddine, K. ^{[13
]}

Zhang, T. ^{[14
]}

机构：

[1] Natl Canc Ctr Hosp East, Med Oncol, Kashiwa, Chiba, Japan

[2] Univ Utah Hlth, Huntsman Canc Inst, Oncol Internal Med Dept, Salt Lake City, UT USA

[3] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Oncol, Boston, MA USA

[4] Univ Calif San Diego UCSD, Med, La Jolla, CA USA

[5] Studienpraxis Urol, Clin Trial Unit, Nuertingen, Germany

[6] Hosp Duran & Reynals, ICO Inst Catala Oncol Hosp, Dept Med Oncol, Barcelona, Spain

[7] Eli Lilly & Co, Oncol, New York, NY USA

[8] Loxo Oncol Inc, Clin Sci, South San Francisco, CA USA

[9] Eli Lilly & Co, Med, West Ryde, NSW, Australia

[10] Eli Lilly & Co, Oncol, Indianapolis, IN USA

[11] Eli Lilly Suisse SA, Oncol Dept, Vernie, Switzerland

[12] Eli Lilly & Co, Stat Dept, Indianapolis, IN USA

[13] Eli Lilly France, Global Clin Dev, Neuilly sur Seine, France

[14] UT Southwestern Med Ctr, Simmons Comprehens Canc Ctr, Internal Med Dept, Dallas, TX USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.791

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

284TiP

引用

页码：S1582 / S1583

页数：2

共 50 条

[21] ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
Armstrong, Andrew J.
Szmulewitz, Russell Z.
Petrylak, Daniel P.
Holzbeierlein, Jeffrey
Villers, Arnauld
Azad, Arun
Alcaraz, Antonio
Alekseev, Boris
Iguchi, Taro
Shore, Neal D.
Rosbrook, Brad
Sugg, Jennifer
Baron, Benoit
Chen, Lucy
Stenzl, Arnulf
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (32) : 2974 - +
[22] Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Ryan, Charles J.
Smith, Matthew R.
Fizazi, Karim
Saad, Fred
Mulders, Peter F. A.
Sternberg, Cora N.
Miller, Kurt
Logothetis, Christopher J.
Shore, Neal D.
Small, Eric J.
Carles, Joan
Flaig, Thomas W.
Taplin, Mary-Ellen
Higano, Celestia S.
de Souza, Paul
de Bono, Johann S. s
Griffin, Thomas W.
De Porre, Peter
Yu, Margaret K.
Park, Youn C.
Li, Jinhui
Kheoh, Thian
Naini, Vahid
Molina, Arturo
Rathkopf, Dana E.
LANCET ONCOLOGY, 2015, 16 (02): : 152 - 160
[23] Darolutamide plus androgen-deprivation therapy in patients with high-risk biochemical recurrence of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP)
Chehrazi-Raffle, Alex
Morgans, Alicia K.
Gschwed, Jurgen E.
Shore, Neal D.
Ross, Ashley
Feng, Felix Y.
Hope, Thomas A.
Nordquist, Luke
Niazi, Tamim
Trandafir, Lucia
Le Berre, Marie-Aude
Kuss, Iris
Joensuu, Heikki
Fizazi, Karim
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[24] Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)
Armstrong, A. J.
Iguchi, T.
Azad, A. A.
Szmulewitz, R. Z.
Holzbeierlein, J.
Villers, A.
Alcaraz, A.
Alekseev, B. Y.
Shore, N. D.
Petrylak, D. P.
Rosbrook, B.
Zohren, F.
Yamada, S.
Haas, G. P.
Stenzl, A.
ANNALS OF ONCOLOGY, 2021, 32 : S1300 - S1301
[25] A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401
Kelly, W. K.
Halabi, S.
Carducci, M. A.
George, D. J.
Mahoney, J. F.
Stadler, W. M.
Morris, M. J.
Kantoff, P. W.
Monk, J. P., III
Small, E. J.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
[26] Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase III, randomized, double-blind, placebo-controlled study (ARASTEP)
Morgans, A. K.
Gschwend, J. E.
Shore, N. D.
Ross, A.
Feng, F.
Hope, T.
Trandafir, L.
Le Berre, M-A.
Kuss, I.
Joensuu, H.
Fizazi, K.
ANNALS OF ONCOLOGY, 2023, 34 : S997 - S998
[27] Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
Pili, Roberto
Haggman, Michael
Stadler, Walter M.
Gingrich, Jeffrey R.
Assikis, Vasileios J.
Bjork, Anders
Nordle, Orjan
Forsberg, Goran
Carducci, Michael A.
Armstrong, Andrew J.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (30) : 4022 - 4028
[28] A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel/Prednisolone in Patients with Hormone-Refractory Prostate Cancer
Horti, Jozsef
Widmark, Anders
Stenzl, Arnulf
Federico, Miriam H.
Abratt, Raymond P.
Sanders, Nick
Pover, Gillian M.
Bodrogi, Istvan
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2009, 24 (02) : 175 - 180
[29] Effects of abiraterone acetate plus prednisone/prednisolone in high and low risk metastatic hormone sensitive prostate cancer
Hoyle, A. P.
Ali, S. A.
James, N. D.
Parker, C. C.
Cook, A. D.
Attard, G.
Chowdhury, S.
Cross, W.
Dearnaley, D. P.
de Bono, J. S.
Gilson, C. E.
Gillessen, S.
Jones, R.
Matheson, D.
Mason, M. D.
Ritchie, A.
Russell, M.
Parmar, M. K.
Sydes, M. R.
Clarke, N. W.
ANNALS OF ONCOLOGY, 2018, 29 : 722 - 722
[30] Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study
Uemura, Hirotsugu
Arai, Gaku
Uemura, Hiroji
Suzuki, Hiroyoshi
Iijima, Kazuyoshi
Nishimura, Kazuo
Fujii, Koji
Hatayama, Tomoyoshi
Aoyama, Junya
Deprince, Kris
Lopez-Gitlitz, Angela
McCarthy, Sharon
Larsen, Julie S.
Li, Jinhui
Chi, Kim N.
INTERNATIONAL JOURNAL OF UROLOGY, 2021, 28 (03) : 280 - 287

← 1 2 3 4 5 →